Emily Hibbitts

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group

D. Rodeberg, S. Spunt, S. Skapek, 2019, Cancer medicine.

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.

A. Naranjo, J. Gastier-Foster, H. Shimada, 2020, European journal of cancer.

Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).

A. Naranjo, W. London, R. Bagatell, 2018, European journal of cancer.

The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma

A. Naranjo, F. Balis, R. Bagatell, 2020, Pediatric blood & cancer.

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

M. Loh, N. Heerema, S. Hunger, 2022, Blood.

Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

James R. Anderson, D. Green, J. Dome, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.

R. Randall, F. Laurie, A. Pappo, 2019, The Lancet. Oncology.

Impaired neurocognitive functioning 3 months following diagnosis of high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group

P. Hinds, N. Winick, K. Hardy, 2023, Pediatric blood & cancer.